Accelerate Your Research with iPSC-Derived Human Neurons and Glia from BrainXell

BrainXell offers the most comprehensive portfolio of high-purity iPSC-derived human neurons and glia, sourced from control, edited and disease lines, to advance translational research and drive drug discovery. Subtype-specific human cells of the central nervous system are invaluable tools for advancing our understanding of various disorders, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), epilepsy, depression, and more. By generating terminally differentiated neurons, astrocytes, and microglia from induced pluripotent stem cells (iPSCs), researchers gain access to a virtually unlimited supply of these highly relevant models. These cells can be derived from both control and disease lines, sourced from publicly available disease banks or created through precise DNA editing. The resulting cells are versatile, supporting traditional 2D cultures or incorporation into complex 3D models, expanding the possibilities for groundbreaking research. We believe model systems employed in biomedical research should have the highest possible relevance to the normal human physiology and disease pathophysiology. Thus, the company was built to provide neurons and glia that can replace the non-human and/or immortalized cell lines traditionally utilized early in drug discovery. We aim to provide cryopreserved cells, medium supplements, and experimental protocols optimized for use single experiments as well in high-throughput screening (HTS). This webinar will highlight the BrainXell portfolio, including newly released midbrain dopaminergic neurons, sensory neurons (nociceptors), and oligodendrocytes, which can be made from a variety or iPSC lines.